212 related articles for article (PubMed ID: 2013146)
21. Challenges to implementing the current pediatric cholesterol screening guidelines into practice.
Dennison BA; Jenkins PL; Pearson TA
Pediatrics; 1994 Sep; 94(3):296-302. PubMed ID: 8065853
[TBL] [Abstract][Full Text] [Related]
22. Screening for coronary heart disease risk in the elderly: total cholesterol versus high-density lipoprotein-cholesterol.
Kligman EW; Watkins AJ
Am J Prev Med; 1991; 7(5):263-7. PubMed ID: 1790030
[TBL] [Abstract][Full Text] [Related]
23. Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes.
Avins AL; Browner WS
JAMA; 1998 Feb; 279(6):445-9. PubMed ID: 9466637
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of a multidisciplinary partnership to improve cardiac wellness: an opportunity for pharmacists.
Miller SW; Darsey E; Heard TJ; Williams J; Kelly M; Norman A; Ter Riet LB
Consult Pharm; 2010 Feb; 25(2):105-16. PubMed ID: 20211823
[TBL] [Abstract][Full Text] [Related]
25. Achieving National Cholesterol Education Program goals in coronary artery disease.
Rondina MT; Zebrack JS
Prev Cardiol; 2005; 8(1):18-22. PubMed ID: 15722690
[TBL] [Abstract][Full Text] [Related]
26. Distribution of lipid phenotypes in community-living men with coronary heart disease. High prevalence of isolated low levels of high-density lipoprotein cholesterol.
Rubins HB; Schectman G; Wilt TJ; Iwane MK
Arch Intern Med; 1992 Dec; 152(12):2412-6. PubMed ID: 1456850
[TBL] [Abstract][Full Text] [Related]
27. Metabolic disorders contribute to subclinical coronary atherosclerosis in patients with coronary calcification.
Superko HR; Hecht HS
Am J Cardiol; 2001 Aug; 88(3):260-4. PubMed ID: 11472704
[TBL] [Abstract][Full Text] [Related]
28. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?
Grover SA; Coupal L; Hu XP
JAMA; 1995 Sep; 274(10):801-6. PubMed ID: 7650803
[TBL] [Abstract][Full Text] [Related]
29. Lipid screening: is it enough to measure total cholesterol concentration?
Neil HA; Mant D; Jones L; Morgan B; Mann JI
BMJ; 1990 Sep; 301(6752):584-7. PubMed ID: 2082960
[TBL] [Abstract][Full Text] [Related]
30. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
31. Relationship of subclinical coronary atherosclerosis and National Cholesterol Education Panel guidelines in asymptomatic Brazilian men.
Nasir K; Santos RD; Roguin A; Carvalho JA; Meneghello R; Blumenthal RS
Int J Cardiol; 2006 Mar; 108(1):68-75. PubMed ID: 16516700
[TBL] [Abstract][Full Text] [Related]
32. Comparisons of referral criteria for public screening of blood cholesterol levels.
Wones RG; Kerman KM; Hissa DC; Meloy N; Stein EA
Public Health Rep; 1989; 104(5):425-32. PubMed ID: 2508171
[TBL] [Abstract][Full Text] [Related]
33. Triglyceride, high density lipoprotein, and coronary heart disease.
Consens Statement; 1992 Feb 26-28; 10(2):1-28. PubMed ID: 1286136
[TBL] [Abstract][Full Text] [Related]
34. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
Keevil JG; Cullen MW; Gangnon R; McBride PE; Stein JH
Circulation; 2007 Mar; 115(11):1363-70. PubMed ID: 17353444
[TBL] [Abstract][Full Text] [Related]
35. LDL-cholesterol versus non-HDL-to-HDL-cholesterol ratio and risk for coronary heart disease in type 2 diabetes.
Eliasson B; Gudbjörnsdottir S; Zethelius B; Eeg-Olofsson K; Cederholm J;
Eur J Prev Cardiol; 2014 Nov; 21(11):1420-8. PubMed ID: 23774274
[TBL] [Abstract][Full Text] [Related]
36. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
37. Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey.
Ko M; Kim MT; Nam JJ
Int J Cardiol; 2006 Jun; 110(2):184-90. PubMed ID: 16412525
[TBL] [Abstract][Full Text] [Related]
38. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events.
Ito MK; Delucca GM; Aldridge MA
J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):129-35. PubMed ID: 11509919
[TBL] [Abstract][Full Text] [Related]
39. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
40. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
